X
<

What to Expect from Colgate-Palmolive’s 2Q17 Earnings

PART:
1 2 3 4 5 6
Part 6
What to Expect from Colgate-Palmolive’s 2Q17 Earnings PART 6 OF 6

Analyst Recommendations for Colgate-Palmolive Stock

Rating and target price

The majority of analysts remain neutral on Colgate-Palmolive (CL) stock, since the company’s volumes continue to decline on the back of moderating category growth. However, through its cost-saving measures, the company remains successful in driving margins growth. Analysts on average maintain a consensus rating of 2.8 on a scale of 1.0 (“strong buy”) to 5.0 (“strong sell”). Of the 22 analysts covering CL stock, 14.0% maintain a “buy” rating, and 86.0% recommend a “hold.” As of July 13, 2017, the company was trading 4.3% below the analysts’ 12-month target price recommendation of $75.37.

Analyst Recommendations for Colgate-Palmolive Stock

Interested in CL? Don't miss the next report.

Receive e-mail alerts for new research on CL

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Peer comparisons

Analysts continue to maintain a neutral outlook on consumer product companies as the slowdown in sales is keeping them on the sidelines. Of the 21 analysts providing ratings for Procter & Gamble (PG) stock, 38.0% have rated it a “buy,” 52.0% have maintained a “hold,” and 10.0% have recommended a “sell.” Of the 15 analysts covering Kimberly-Clark (KMB) stock, 7.0% have rated it a “buy,” 86.0% have maintained a “hold,” and 7.0% have recommended a “sell.” As for Clorox (CLX), 11.0% of the 18 analysts covering the stock have recommended a “buy,” 78.0% have rated it a “hold,” and 11.0% have rated it a “sell.”

Valuation summary

As of July 13, 2017, Colgate-Palmolive stock was trading at a 12-month forward PE (price-to-earnings) multiple of 24.3x, which is above the peer average of 22.8x. The company’s stock is also trading at a premium when compared to the broader index. The S&P 500 Index (SPX-INDEX) and the Consumer Staples Select Sector SPDR ETF (XLP) were trading at forward PE multiples of 18.0x and 21.8x, respectively. On the same date, Procter & Gamble, Kimberly-Clark, and Clorox were trading at forward PE ratios of 21.5x, 19.5x, and 23.5x, respectively.

X

Please select a profession that best describes you: